{ "version": "2.2", "instance": { "arch20230928_s1a.htm": { "nsprefix": "arch", "nsuri": "http://www.archtherapeutics.com/20220930", "dts": { "schema": { "local": [ "arch-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "arch-20220930_cal.xml" ] }, "definitionLink": { "local": [ "arch-20220930_def.xml" ] }, "labelLink": { "local": [ "arch-20220930_lab.xml" ] }, "presentationLink": { "local": [ "arch-20220930_pre.xml" ] }, "inline": { "local": [ "arch20230928_s1a.htm" ] } }, "keyStandard": 220, "keyCustom": 76, "axisStandard": 27, "axisCustom": 0, "memberStandard": 26, "memberCustom": 88, "hidden": { "total": 28, "http://xbrl.sec.gov/dei/2023": 4, "http://fasb.org/us-gaap/2023": 15, "http://www.archtherapeutics.com/20220930": 9 }, "contextCount": 443, "entityCount": 1, "segmentCount": 121, "elementCount": 527, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1059, "http://xbrl.sec.gov/dei/2023": 18 }, "report": { "R1": { "role": "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2022-09-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-09-30", "name": "us-gaap:CommitmentsAndContingencies", "unitRef": "USD", "xsiNil": "true", "lang": null, "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R3": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "longName": "003 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2023-04-01_2023-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC", "longName": "005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "longName": "006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R8": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "longName": "007 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "longName": "008 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-09-30_StatementScenarioAxis-AdjustedMember", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R10": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited", "longName": "009 - Statement - Consolidated Statements of Operations (Unaudited)", "shortName": "Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "d_2023-04-01_2023-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "longName": "010 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "11", "firstAnchor": { "contextRef": "i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R12": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "longName": "011 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "12", "firstAnchor": { "contextRef": "i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R13": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "longName": "012 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "13", "firstAnchor": { "contextRef": "i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R14": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "longName": "013 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "14", "firstAnchor": { "contextRef": "i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R15": { "role": "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "longName": "014 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "15", "firstAnchor": { "contextRef": "d_2023-01-01_2023-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-06-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R16": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business", "longName": "015 - Disclosure - Note 1 - Description of Business", "shortName": "Note 1 - Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R17": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-", "longName": "016 - Disclosure - Note 2 - Summary Of Significant Accounting Policies", "shortName": "Note 2 - Summary Of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "longName": "017 - Disclosure - Note 3 - Property and Equipment", "shortName": "Note 3 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-", "longName": "018 - Disclosure - Note 4 - Inventories", "shortName": "Note 4 - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "longName": "019 - Disclosure - Note 5 - Insurance Premium Financing", "shortName": "Note 5 - Insurance Premium Financing", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30_DebtInstrumentAxis-InsurancePremiumFinancingMember", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "longName": "020 - Disclosure - Note 6 - Registered Direct Offerings", "shortName": "Note 6 - Registered Direct Offerings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "arch:StockholdersEquityNoteDirectOfferingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "arch:StockholdersEquityNoteDirectOfferingsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "longName": "021 - Disclosure - Note 7 - Derivative Liabilities", "shortName": "Note 7 - Derivative Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "longName": "022 - Disclosure - Note 8 - October 2019 Registered Direct Offering", "shortName": "Note 8 - October 2019 Registered Direct Offering", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "arch:StockholdersEquityNoteDirectOffering2019OctoberTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "longName": "023 - Disclosure - Note 9 - 2021 Registered Direct Offering", "shortName": "Note 9 - 2021 Registered Direct Offering", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "longName": "024 - Disclosure - Note 10 - 2022 Convertible Note Offering", "shortName": "Note 10 - 2022 Convertible Note Offering", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30_DebtInstrumentAxis-Notes2022Member", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "longName": "025 - Disclosure - Note 11 - Series 1 and Series 2 Convertible Notes", "shortName": "Note 11 - Series 1 and Series 2 Convertible Notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30_DebtInstrumentAxis-Series12ConvertibleNotesMember", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "longName": "026 - Disclosure - Note 12 - Income Taxes", "shortName": "Note 12 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "longName": "027 - Disclosure - Note 13- Payroll Protection Program Loan", "shortName": "Note 13- Payroll Protection Program Loan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "arch:PayrollProtectionProgramLoanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "arch:PayrollProtectionProgramLoanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "longName": "028 - Disclosure - Note 14 - Stock-based Compensation", "shortName": "Note 14 - Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "longName": "029 - Disclosure - Note 15 - Commitments and Contingencies", "shortName": "Note 15 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-16-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "longName": "030 - Disclosure - Note 16 - Risks and Uncertainties - COVID-19 and Geopolitical Conflicts", "shortName": "Note 16 - Risks and Uncertainties - COVID-19 and Geopolitical Conflicts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "arch:Covid19DisclsoureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business", "longName": "031 - Disclosure - Note 1 - Basis of Presentation and Description of Business", "shortName": "Note 1 - Basis of Presentation and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "032 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "longName": "033 - Disclosure - Note 3 - Property and Equipment (10Q)", "shortName": "Note 3 - Property and Equipment (10Q)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q", "longName": "034 - Disclosure - Note 4 - Inventories (10Q)", "shortName": "Note 4 - Inventories (10Q)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A", "longName": "035 - Disclosure - Note 5 - Insurance Premium Financing", "shortName": "Note 5 - Insurance Premium Financing", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30_DebtInstrumentAxis-InsurancePremiumFinancingMember", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "longName": "036 - Disclosure - Note 6 - Stock-based Compensation", "shortName": "Note 6 - Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "longName": "037 - Disclosure - Note 7 - Registered Direct Offerings", "shortName": "Note 7 - Registered Direct Offerings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "longName": "038 - Disclosure - Note 8 - Derivative Liabilities", "shortName": "Note 8 - Derivative Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "39", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "longName": "039 - Disclosure - Note 9 - October 2019 Registered Direct Offering", "shortName": "Note 9 - October 2019 Registered Direct Offering", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "40", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "arch:StockholdersEquityNoteDirectOffering2019OctoberTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "longName": "040 - Disclosure - Note 10 - 2021 Registered Direct Offerings", "shortName": "Note 10 - 2021 Registered Direct Offerings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "41", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "longName": "041 - Disclosure - Note 11 - 2022 Convertible Note Offering, Second Notes Offering, and Third Notes Offering", "shortName": "Note 11 - 2022 Convertible Note Offering, Second Notes Offering, and Third Notes Offering", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "42", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30_DebtInstrumentAxis-Notes2022Member", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "longName": "042 - Disclosure - Note 12 - Series Convertible Notes", "shortName": "Note 12 - Series Convertible Notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "43", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30_DebtInstrumentAxis-Series12ConvertibleNotesMember", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-13-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "longName": "043 - Disclosure - Note 13 - Risks and Uncertainties - COVID-19 and Geopolitical Conflicts", "shortName": "Note 13 - Risks and Uncertainties - COVID-19 and Geopolitical Conflicts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "44", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "arch:Covid19DisclsoureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "longName": "044 - Disclosure - Note 14 - Shareholder Advances and Prefundings Related to The Anticipated Bridge Financing", "shortName": "Note 14 - Shareholder Advances and Prefundings Related to The Anticipated Bridge Financing", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "45", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "arch:ShareholderAdvancesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "arch:ShareholderAdvancesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "longName": "045 - Disclosure - Note 15 - Subsequent Events", "shortName": "Note 15 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "46", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-tables", "longName": "046 - Disclosure - Note 3 - Property and Equipment (Tables)", "shortName": "Note 3 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-tables", "longName": "047 - Disclosure - Note 4 - Inventories (Tables)", "shortName": "Note 4 - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-tables", "longName": "048 - Disclosure - Note 7 - Derivative Liabilities (Tables)", "shortName": "Note 7 - Derivative Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-tables", "longName": "049 - Disclosure - Note 10 - 2022 Convertible Note Offering (Tables)", "shortName": "Note 10 - 2022 Convertible Note Offering (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "arch:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-tables", "longName": "050 - Disclosure - Note 12 - Income Taxes (Tables)", "shortName": "Note 12 - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "longName": "051 - Disclosure - Note 14 - Stock-based Compensation (Tables)", "shortName": "Note 14 - Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-tables", "longName": "052 - Disclosure - Note 3 - Property and Equipment (10Q) (Tables)", "shortName": "Note 3 - Property and Equipment (10Q) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q-tables", "longName": "053 - Disclosure - Note 4 - Inventories (10Q) (Tables)", "shortName": "Note 4 - Inventories (10Q) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables", "longName": "054 - Disclosure - Note 6 - Stock-based Compensation (Tables)", "shortName": "Note 6 - Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-tables", "longName": "055 - Disclosure - Note 8 - Derivative Liabilities (Tables)", "shortName": "Note 8 - Derivative Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables", "longName": "056 - Disclosure - Note 11 - 2022 Convertible Note Offering, Second Notes Offering, and Third Notes Offering (Tables)", "shortName": "Note 11 - 2022 Convertible Note Offering, Second Notes Offering, and Third Notes Offering (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "d_2022-10-01_2023-06-30", "name": "arch:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business-details-textual", "longName": "057 - Disclosure - Note 1 - Description of Business (Details Textual)", "shortName": "Note 1 - Description of Business (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-details-textual", "longName": "058 - Disclosure - Note 3 - Property and Equipment (Details Textual)", "shortName": "Note 3 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "d_2023-04-01_2023-06-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details", "longName": "059 - Disclosure - Note 3 - Property and Equipment - Property and Equipment (Details)", "shortName": "Note 3 - Property and Equipment - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R61": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details", "longName": "060 - Disclosure - Note 5 - Inventories - Inventories (Details)", "shortName": "Note 5 - Inventories - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "longName": "061 - Disclosure - Note 5 - Insurance Premium Financing (Details Textual)", "shortName": "Note 5 - Insurance Premium Financing (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "i_2022-07-31_DebtInstrumentAxis-InsurancePremiumFinancingMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "longName": "062 - Disclosure - Note 6 - Registered Direct Offerings (Details Textual)", "shortName": "Note 6 - Registered Direct Offerings (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2016-09-30", "name": "arch:ShelfRegistrationStatementMaximumAmountAuthorized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "arch:StockholdersEquityNoteDirectOfferingsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-09-30_ClassOfWarrantOrRightAxis-ClassOfSeriesFWarrantMember", "name": "arch:ClassOfWarrantOrRightAcquiredUponExercise", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "arch:StockholdersEquityNoteDirectOfferingsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R64": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "longName": "063 - Disclosure - Note 7 - Derivative Liabilities (Details Textual)", "shortName": "Note 7 - Derivative Liabilities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "d_2023-04-01_2023-06-30", "name": "us-gaap:UnrealizedGainLossOnDerivatives", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30_ClassOfWarrantOrRightAxis-SeriesFWarrantMember", "name": "us-gaap:UnrealizedGainLossOnDerivatives", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R65": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "longName": "064 - Disclosure - Note 7 - Derivative Liabilities - Fair Value of Derivative Liability (Details)", "shortName": "Note 7 - Derivative Liabilities - Fair Value of Derivative Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2021-09-30_DerivativeInstrumentRiskAxis-SeriesFWarrantDerivativeMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-10-09_DerivativeInstrumentRiskAxis-SeriesFWarrantDerivativeMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R66": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "longName": "065 - Disclosure - Note 7 - Derivative Liabilities - Derivative Liability Value Assumptions (Details)", "shortName": "Note 7 - Derivative Liabilities - Derivative Liability Value Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "i_2021-09-30_DerivativeInstrumentRiskAxis-SeriesFWarrantDerivativeMember_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2021-09-30_DerivativeInstrumentRiskAxis-SeriesFWarrantDerivativeMember_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "longName": "066 - Disclosure - Note 8 - October 2019 Registered Direct Offering (Details Textual)", "shortName": "Note 8 - October 2019 Registered Direct Offering (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "d_2021-02-17_2021-02-17", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-09-30_ClassOfWarrantOrRightAxis-ClassOfSeriesIWarrantMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "arch:StockholdersEquityNoteDirectOffering2019OctoberTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R68": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "longName": "067 - Disclosure - Note 9 - 2021 Registered Direct Offering (Details Textual)", "shortName": "Note 9 - 2021 Registered Direct Offering (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "d_2021-02-17_2021-02-17", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R69": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "longName": "068 - Disclosure - Note 10 - 2022 Convertible Note Offering (Details Textual)", "shortName": "Note 10 - 2022 Convertible Note Offering (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "d_2021-02-17_2021-02-17", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R70": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "longName": "069 - Disclosure - Note 11 - 2022 Convertible Note Offering - Summary of Valuation Assumptions for Warrants (Details)", "shortName": "Note 11 - 2022 Convertible Note Offering - Summary of Valuation Assumptions for Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "i_2022-07-06_ClassOfWarrantOrRightAxis-InvestorWarrantsMember", "name": "us-gaap:SharePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "arch:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "longName": "070 - Disclosure - Note 11 - Series 1 and Series 2 Convertible Notes (Details Textual)", "shortName": "Note 11 - Series 1 and Series 2 Convertible Notes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "d_2022-07-06_2022-07-06_DebtConversionByUniqueDescriptionAxis-Series2NotesConvertedToSeniorSecuredConvertibleNotesMember", "name": "us-gaap:DebtConversionOriginalDebtAmount1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2015-06-30_ClassOfWarrantOrRightAxis-SeriesDWarrantMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R72": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual", "longName": "071 - Disclosure - Note 12 - Income Taxes (Details Textual)", "shortName": "Note 12 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details", "longName": "072 - Disclosure - Note 12 - Income Taxes - Net Deferred Tax Assets (Details)", "shortName": "Note 12 - Income Taxes - Net Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "i_2022-09-30", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-09-30", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details", "longName": "073 - Disclosure - Note 12 - Income Taxes - Computation of Provision (benefits) Income Taxes from Statutory Federal Income Tax Rate (Details)", "shortName": "Note 12 - Income Taxes - Computation of Provision (benefits) Income Taxes from Statutory Federal Income Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "longName": "074 - Disclosure - Note 13- Payroll Protection Program Loan (Details Textual)", "shortName": "Note 13- Payroll Protection Program Loan (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "d_2021-10-01_2022-09-30_DebtInstrumentAxis-PaycheckProtectionProgramLoanMember", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "arch:PayrollProtectionProgramLoanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30_DebtInstrumentAxis-PaycheckProtectionProgramLoanMember", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "arch:PayrollProtectionProgramLoanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "longName": "075 - Disclosure - Note 14 - Stock-based Compensation (Details Textual)", "shortName": "Note 14 - Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R77": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "longName": "076 - Disclosure - Note 14 - Stock-based Compensation - Stock Compensation Activity (Details)", "shortName": "Note 14 - Stock-based Compensation - Stock Compensation Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "i_2022-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R78": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "longName": "077 - Disclosure - Note 14 - Stock-based Compensation - Restricted Stock Activity (Details)", "shortName": "Note 14 - Stock-based Compensation - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "i_2023-03-31_PlanNameAxis-The2013PlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2021-10-01_2022-09-30_PlanNameAxis-The2013PlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R79": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "longName": "078 - Disclosure - Note 14 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details)", "shortName": "Note 14 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "i_2023-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2020-10-01_2021-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R80": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual", "longName": "079 - Disclosure - Note 15 - Commitments and Contingencies (Details Textual)", "shortName": "Note 15 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "i_2022-09-30", "name": "us-gaap:AccruedRentCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-09-30", "name": "us-gaap:AccruedRentCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business-details-textual", "longName": "080 - Disclosure - Note 1 - Basis of Presentation and Description of Business (Details Textual)", "shortName": "Note 1 - Basis of Presentation and Description of Business (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R82": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "081 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "d_2023-04-01_2023-06-30", "name": "us-gaap:GainLossOnSaleOfDerivatives", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-details-textual", "longName": "082 - Disclosure - Note 3 - Property and Equipment (10Q) (Details Textual)", "shortName": "Note 3 - Property and Equipment (10Q) (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "d_2023-04-01_2023-06-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R84": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "longName": "083 - Disclosure - Note 3 - Property and Equipment - Property and Equipment (10Q) (Details)", "shortName": "Note 3 - Property and Equipment - Property and Equipment (10Q) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R85": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details", "longName": "084 - Disclosure - Note 4 - Inventories - Inventories (10Q) (Details)", "shortName": "Note 4 - Inventories - Inventories (10Q) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R86": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9", "longName": "085 - Disclosure - Note 5 - Insurance Premium Financing (Details Textual)", "shortName": "Note 5 - Insurance Premium Financing (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "i_2022-07-31_DebtInstrumentAxis-InsurancePremiumFinancingMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R87": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "longName": "086 - Disclosure - Note 6 - Stock-based Compensation (Details Textual)", "shortName": "Note 6 - Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R88": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details", "longName": "087 - Disclosure - Note 6 - Stock-based Compensation - Stock Compensation Activity (Details)", "shortName": "Note 6 - Stock-based Compensation - Stock Compensation Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "i_2022-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R89": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details", "longName": "088 - Disclosure - Note 6 - Stock-based Compensation - Restricted Stock Activity (Details)", "shortName": "Note 6 - Stock-based Compensation - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "i_2022-03-31_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-03-31_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "longName": "089 - Disclosure - Note 6 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details)", "shortName": "Note 6 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "i_2023-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-09-30_PlanNameAxis-The2013PlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R91": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "longName": "090 - Disclosure - Note 7 - Registered Direct Offerings (Details Textual)", "shortName": "Note 7 - Registered Direct Offerings (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "i_2016-09-30", "name": "arch:ShelfRegistrationStatementMaximumAmountAuthorized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "arch:StockholdersEquityNoteDirectOfferingsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R92": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "longName": "091 - Disclosure - Note 8 - Derivative Liabilities (Details Textual)", "shortName": "Note 8 - Derivative Liabilities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "i_2023-03-10", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R93": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details", "longName": "092 - Disclosure - Note 8 - Derivative Liabilities - Fair Value of Derivative Liability (Details)", "shortName": "Note 8 - Derivative Liabilities - Fair Value of Derivative Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "i_2022-09-30_DerivativeInstrumentRiskAxis-SeriesGWarrantMember_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2022-10-01_2023-06-30_DerivativeInstrumentRiskAxis-SeriesGWarrantMember_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R94": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "longName": "093 - Disclosure - Note 8 - Derivative Liabilities - Derivative Liability Value Assumptions (Details)", "shortName": "Note 8 - Derivative Liabilities - Derivative Liability Value Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "i_2023-03-10_DerivativeInstrumentRiskAxis-SeriesGWarrantMember_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-03-10_DerivativeInstrumentRiskAxis-SeriesHWarrantMember_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R95": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual", "longName": "094 - Disclosure - Note 9 - October 2019 Registered Direct Offering (Details Textual)", "shortName": "Note 9 - October 2019 Registered Direct Offering (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "d_2021-02-17_2021-02-17", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2019-10-16_2019-10-16_SubsidiarySaleOfStockAxis-RegisteredDirectOffering2019Member", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "arch:StockholdersEquityNoteDirectOffering2019OctoberTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R96": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "longName": "095 - Disclosure - Note 10 - 2021 Registered Direct Offerings (Details Textual)", "shortName": "Note 10 - 2021 Registered Direct Offerings (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "d_2021-02-17_2021-02-17", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": null }, "R97": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "longName": "096 - Disclosure - Note 11 - 2022 Convertible Note Offering, Second Notes Offering, and Third Notes Offering (Details Textual)", "shortName": "Note 11 - 2022 Convertible Note Offering, Second Notes Offering, and Third Notes Offering (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "d_2021-02-17_2021-02-17", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-18_2023-01-18", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R98": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "longName": "097 - Disclosure - Note 11 - 2022 Convertible Note Offering and Second Notes Offering - Summary of Valuation Assumptions for Warrants (Details)", "shortName": "Note 11 - 2022 Convertible Note Offering and Second Notes Offering - Summary of Valuation Assumptions for Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "i_2022-07-06_ClassOfWarrantOrRightAxis-InvestorWarrantsMember", "name": "us-gaap:SharePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "arch:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-01-18_ClassOfWarrantOrRightAxis-SecondWarrantsMember", "name": "us-gaap:SharePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R99": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "longName": "098 - Disclosure - Note 12 - Series Convertible Notes (Details Textual)", "shortName": "Note 12 - Series Convertible Notes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "d_2023-07-12_2023-07-12_DebtConversionByUniqueDescriptionAxis-ConversionOfSeries1ConvertibleNotesIntoCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-12_2023-07-12_DebtConversionByUniqueDescriptionAxis-ConversionOfSeries1ConvertibleNotesIntoCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "longName": "099 - Disclosure - Note 14 - Shareholder Advances and Prefundings Related to The Anticipated Bridge Financing (Details Textual)", "shortName": "Note 14 - Shareholder Advances and Prefundings Related to The Anticipated Bridge Financing (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "d_2023-01-01_2023-05-12", "name": "arch:ProceedsFromShareholderAdvances", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "arch:ShareholderAdvancesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-05-31", "name": "arch:AdvanceExpectedToRollIntoNeartermCapitalRaise", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "arch:ShareholderAdvancesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } }, "R101": { "role": "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "longName": "100 - Disclosure - Note 15 - Subsequent Events (Details Textual)", "shortName": "Note 15 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-07-07_SubsequentEventTypeAxis-SubsequentEventMember", "name": "arch:UplistTransactionPurchasePriceRateOverPricePaidByInvestor", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "arch20230928_s1a.htm", "unique": true } } }, "tag": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r46" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r80", "r109", "r393", "r403", "r404", "r410", "r443", "r531" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r293", "r294" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "negatedLabel": "Issuances", "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r11", "r58" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfShortTermDebt", "negatedLabel": "Repayment of insurance premium financing", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r104", "r156", "r229", "r235", "r236", "r237", "r238", "r239", "r240", "r245", "r252", "r253", "r254" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Beginning balance at September 30, 2021", "negatedPeriodEndLabel": "Ending balance at September 30, 2022", "label": "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "negatedLabel": "Beginning balance at September 30, 2020", "periodStartLabel": "Beginning balance at September 30, 2022", "periodEndLabel": "Ending balance at March 31, 2023", "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r11", "r57" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r4" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r20", "r133", "r158", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r342", "r343", "r344", "r361", "r531", "r569", "r610", "r611" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r293", "r294" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements", "negatedLabel": "Exchange of warrants into common stock", "documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r11", "r58" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Shareholder and Third-Party Advances related to Bridge Financing", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r73", "r118" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentCarryingAmount", "terseLabel": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r13", "r120", "r255" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_DerivativesAndFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesAndFairValueTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities" ], "lang": { "en-us": { "role": { "label": "Derivatives and Fair Value [Text Block]", "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities." } } }, "auth_ref": [ "r114", "r115" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r313" ] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConvertibleDebt", "terseLabel": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r13", "r120", "r621" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r14" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Awarded, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r297" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315" ] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments, Liabilities [Member]", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Forfeited/Cancelled, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r299" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r176", "r284", "r548", "r549", "r563" ] }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments", "terseLabel": "Debt Instrument, Convertible, Number of Equity Instruments", "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity." } } }, "auth_ref": [ "r22", "r44", "r107", "r108", "r232" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r136" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r368", "r376" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Loss per share - basic and diluted" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r176", "r284", "r548", "r563" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r105", "r232" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r61", "r63", "r230", "r370", "r521", "r522" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseRightOfUseAsset", "terseLabel": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r371" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r368", "r376" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligation", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractualObligation", "terseLabel": "Contractual Obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r559" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r17", "r557" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityPeriodicPayment", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityPeriodicPayment", "terseLabel": "Line of Credit Facility, Periodic Payment", "documentation": "Amount of the required periodic payments of both interest and principal." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds received from convertible notes", "terseLabel": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Less - accumulated depreciation, Total", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r41", "r135", "r395" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r92" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r356" ] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r13", "r73", "r74", "r118", "r120", "r162", "r230", "r231", "r232", "r233", "r234", "r236", "r241", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r370", "r520", "r521", "r522", "r523", "r524", "r557" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "http://www.archtherapeutics.com/20220930/role/statement-note-13-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-16-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Non-cash financing activities:" } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Decrease to fair value of derivative", "negatedLabel": "Decrease to fair value of derivative", "terseLabel": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": [ "r3", "r477", "r478", "r479", "r480", "r497" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromWarrantExercises", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r554" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net (decrease) increase in cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r95" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r243", "r277", "r278", "r279", "r280", "r281", "r282", "r378", "r379", "r380", "r521", "r522", "r526", "r527", "r528" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Payment of 2022 Financing debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r29" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash, beginning of year", "periodEndLabel": "Cash, end of year", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r30", "r95", "r154" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentIncreaseAccruedInterest", "terseLabel": "Interest Payable", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r557" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Gain on forgiveness of loan", "negatedLabel": "Gain on forgiveness of loan", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r3", "r42", "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r21", "r231" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r159", "r326", "r328", "r329", "r333", "r336", "r338", "r339", "r340", "r411" ] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Fair value of 2022 Inducement Shares issued (see Note 10)", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r206" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Gross deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r331" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressAddressLine1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentPeriodicPayment", "terseLabel": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r23", "r66" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315" ] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9" ], "lang": { "en-us": { "role": { "label": "Insurance premium financing", "terseLabel": "Short-Term Debt, Total", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r72", "r118", "r531", "r620" ] }, "arch_AccretionOfDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "AccretionOfDebtDiscount", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_AccretionOfDebtDiscount", "terseLabel": "Accretion of Debt Discount", "documentation": "Accretion amount of debt discount." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Inventory allowance", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r52", "r602" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r23", "r162", "r230", "r231", "r232", "r233", "r234", "r236", "r241", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r370", "r520", "r521", "r522", "r523", "r524", "r557" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r375", "r377" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r53", "r54", "r55", "r56", "r431", "r433", "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r456", "r457", "r458", "r459", "r471", "r472", "r473", "r474", "r477", "r478", "r479", "r480", "r493", "r494", "r498", "r500", "r515", "r533", "r535" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information about the period subject to enacted tax laws." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r62", "r124", "r150", "r191", "r369", "r468", "r541", "r625" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r553" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressCityOrTown", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r88" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r24", "r65", "r390", "r441" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressStateOrProvince", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r274" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other (in shares)", "documentation": "Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r52", "r602" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "terseLabel": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r60", "r63", "r572" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r52", "r602" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r3", "r40" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r327" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r601" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r98", "r155" ] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Exercise Price [Member]", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r605" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressPostalZipCode", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r605" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r212", "r213", "r467" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r368", "r376" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r605" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Current portion of accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r45" ] }, "arch_AdjustedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "AdjustedMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C" ], "lang": { "en-us": { "role": { "label": "Adjusted [Member]", "documentation": "Related to an adjusted balance." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r213", "r467" ] }, "arch_GrossProceedsRequiredToRecognizeDeferredAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "GrossProceedsRequiredToRecognizeDeferredAmounts", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_GrossProceedsRequiredToRecognizeDeferredAmounts", "terseLabel": "Gross Proceeds Required to Recognize Deferred Amounts", "documentation": "Represents Gross Proceeds Required to Recognize Deferred Amounts" } } }, "auth_ref": [] }, "arch_AdvanceExpectedToRollIntoNeartermCapitalRaise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "AdvanceExpectedToRollIntoNeartermCapitalRaise", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_AdvanceExpectedToRollIntoNeartermCapitalRaise", "terseLabel": "Advance Expected to Roll Into Near-term Capital Raise", "documentation": "Amount of advance expected to roll into near-term capital raise." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPeriodIncreaseDecrease", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityPeriodIncreaseDecrease", "terseLabel": "Stockholders' Equity, Period Increase (Decrease)", "documentation": "The increase (decrease) in stockholders' equity during the period." } } }, "auth_ref": [ "r5", "r109", "r484", "r507", "r542", "r622" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r93", "r249", "r258", "r523", "r524" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r608" ] }, "arch_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "CommonWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Warrants [Member]", "documentation": "Represents the common warrants" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r17", "r557" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total long-term assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r158", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r341", "r343", "r361", "r569", "r570", "r610" ] }, "arch_FirstInsuranceFundingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "FirstInsuranceFundingMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "First Insurance Funding [Member]", "documentation": "First Insurance Funding" } } }, "auth_ref": [] }, "arch_FinanceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "FinanceAgreementMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Finance Agreement [Member]", "documentation": "Finance agreement" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested and expected to vest weighted average exercise price (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r530" ] }, "arch_ConversionOfShareholderAdvanceIntoUnsecuredConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ConversionOfShareholderAdvanceIntoUnsecuredConvertibleNoteMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Conversion of Shareholder Advance Into Unsecured Convertible Note [Member]", "documentation": "Represents the conversion of shareholder advance into unsecured convertible note." } } }, "auth_ref": [] }, "arch_ConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ConsultantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Consultants [Member]", "documentation": "Related to consultants." } } }, "auth_ref": [] }, "arch_ConversionOfSeries1ConvertibleNotesIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ConversionOfSeries1ConvertibleNotesIntoCommonStockMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Series 1 Convertible Notes Into Common Stock [Member]", "documentation": "Represents the conversion of series 1 convertible notes into common stock." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r573" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r319" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "arch_ConvertibleNotesPayableSeriesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ConvertibleNotesPayableSeriesOneMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Series One [Member]", "documentation": "Represents convertible notes payable series one." } } }, "auth_ref": [] }, "arch_ConvertibleNotesPayableSeriesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ConvertibleNotesPayableSeriesTwoMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Series Two [Member]", "documentation": "Represents convertible notes payable series two." } } }, "auth_ref": [] }, "arch_BlankCheckPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "BlankCheckPreferredStockMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Blank Check Preferred Stock [Member]", "documentation": "Blank Check Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "arch_Covid19DisclsoureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "Covid19DisclsoureTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-13-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-16-risks-and-uncertainties-covid19-and-geopolitical-conflicts" ], "lang": { "en-us": { "role": { "label": "COVID-19 Disclsoure [Text Block]", "documentation": "The complete disclosure for risks and uncertainties related to COVID-19." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputInceptionDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputInceptionDiscountRateMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Inception Discount Rate [Member]", "documentation": "Measurement input using interest rate at inception of contract to determine present value of future cash flows." } } }, "auth_ref": [ "r605" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Long-term assets:" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r606" ] }, "arch_BoardOfDirectorsAndManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "BoardOfDirectorsAndManagementMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Board Of Directors And Management [Member]", "documentation": "Represents Board of Directors and Management." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested and expected to vest, aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r310" ] }, "arch_BoardMemberAndExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "BoardMemberAndExecutiveOfficerMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Board Member and Executive Officer [Member]", "documentation": "Represents board member and executive officer." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r103", "r214", "r215", "r509", "r568" ] }, "arch_DebtConversionPrincipalAndAccruedInterestConversionMultiple": { "xbrltype": "pureItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DebtConversionPrincipalAndAccruedInterestConversionMultiple", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_DebtConversionPrincipalAndAccruedInterestConversionMultiple", "terseLabel": "Debt Conversion, Principal and Accrued Interest Conversion Multiple", "documentation": "The conversion multiple for principal and accrued interest in the event the company exercises the option to convert." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r18", "r158", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r342", "r343", "r344", "r361", "r440", "r517", "r543", "r569", "r610", "r611" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_Revenues", "terseLabel": "Revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r151", "r158", "r189", "r190", "r192", "r195", "r196", "r200", "r201", "r202", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r361", "r387", "r569" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r62", "r241", "r256", "r521", "r522" ] }, "arch_DebtConversionConvertedDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DebtConversionConvertedDebtAmount", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Exchange of Series 2 Convertible Notes into Senior Secured Notes (See Note 10)", "documentation": "The value of the debt that the original debt is being converted into in a noncash (or part noncash) transaction." } } }, "auth_ref": [] }, "arch_CertainInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "CertainInvestorsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Certain Investors [Member]", "documentation": "Represents certain investors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested and expected to vest, shares (in shares)", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r309" ] }, "arch_DebtInstrumentAdditionalIssuanceProductRate": { "xbrltype": "pureItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DebtInstrumentAdditionalIssuanceProductRate", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_DebtInstrumentAdditionalIssuanceProductRate", "terseLabel": "Debt Instrument, Additional Issuance, Product Rate", "documentation": "Product rate of additional issuance of debt instrument." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r188", "r193", "r197", "r199", "r518" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total long-term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r13", "r69", "r70", "r71", "r75", "r158", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r342", "r343", "r344", "r361", "r569", "r610", "r611" ] }, "arch_DebtInstrumentApprovalOfExtensionPercentagePurchase": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DebtInstrumentApprovalOfExtensionPercentagePurchase", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_DebtInstrumentApprovalOfExtensionPercentagePurchase", "terseLabel": "Debt Instrument, Approval of Extension, Percentage Purchase", "documentation": "Percentage of purchase of debt instrument for holders who can approve extension." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "arch_ClassOfSeriesFWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfSeriesFWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Class Of Series F Warrant [Member]", "documentation": "Represents series F warrants." } } }, "auth_ref": [] }, "arch_DebtInstrumentApprovalOfExtensionPurchaseAbovePercentage": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DebtInstrumentApprovalOfExtensionPurchaseAbovePercentage", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_DebtInstrumentApprovalOfExtensionPurchaseAbovePercentage", "terseLabel": "Debt Instrument, Approval of Extension, Purchase Above Percentage", "documentation": "Amount of purchase above percentage needed by holders of debt instrument to approve extension." } } }, "auth_ref": [] }, "arch_CertainInvestorsWithPreexistingRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "CertainInvestorsWithPreexistingRelationshipsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Certain Investors With Pre-existing Relationships [Member]", "documentation": "Related to certain investors with pre-existing relationships." } } }, "auth_ref": [] }, "arch_DebtInstrumentFailureToCompleteUplistTransactionFeePercentageOfOutstandingPrincipal": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DebtInstrumentFailureToCompleteUplistTransactionFeePercentageOfOutstandingPrincipal", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_DebtInstrumentFailureToCompleteUplistTransactionFeePercentageOfOutstandingPrincipal", "terseLabel": "Debt Instrument, Failure to Complete Uplist Transaction Fee, Percentage of Outstanding Principal", "documentation": "The percentage of outstanding principal that will be obligated to pay if an Uplist Transaction is not completed to holders of the debt instrument." } } }, "auth_ref": [] }, "arch_DebtInstrumentInterestRateForAmountOfPrincipalOrInterestNotPaidWhenDue": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DebtInstrumentInterestRateForAmountOfPrincipalOrInterestNotPaidWhenDue", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_DebtInstrumentInterestRateForAmountOfPrincipalOrInterestNotPaidWhenDue", "terseLabel": "Debt Instrument, Interest Rate for Amount of Principal or Interest Not Paid When Due", "documentation": "Represents interest rate for amount of principal or interest that is not paid when due under debt instrument." } } }, "auth_ref": [] }, "arch_DeferredTaxAssetsCapitalizedExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DeferredTaxAssetsCapitalizedExpenditures", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Capitalized expenditures", "documentation": "Deferred tax assets capitalized expenditures." } } }, "auth_ref": [] }, "arch_ClassOfSeriesGWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfSeriesGWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Class Of Series G Warrant [Member]", "documentation": "Represents series G warrants" } } }, "auth_ref": [] }, "arch_DerivativeWarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "DerivativeWarrantLiabilityMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liability [Member]", "documentation": "Related to derivative warrant liability." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "arch_EmployeesDirectorsAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "EmployeesDirectorsAndConsultantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Employees Directors And Consultants [Member]", "documentation": "Represents employees, directors, and consultants." } } }, "auth_ref": [] }, "arch_ClassOfSeriesHWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfSeriesHWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Class Of Series H Warrant [Member]", "documentation": "Represents series H warrants." } } }, "auth_ref": [] }, "arch_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueOfDerivativePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueOfDerivativePercent", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Adjustment to fair value of derivative", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of derivative" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r83", "r121", "r394", "r531", "r558", "r566", "r607" ] }, "arch_EquityOfferingPlacementAgentFeePercentageOfGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "EquityOfferingPlacementAgentFeePercentageOfGrossProceeds", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_EquityOfferingPlacementAgentFeePercentageOfGrossProceeds", "terseLabel": "Equity Offering, Placement Agent Fee, Percentage of Gross Proceeds", "documentation": "Percentage of gross proceeds for placement agent fee under equity offering." } } }, "auth_ref": [] }, "arch_ClassOfSeriesIWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfSeriesIWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Series I Warrant [Member]", "documentation": "Represents class of series I warrant." } } }, "auth_ref": [] }, "arch_ExpireIn2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ExpireIn2023Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Expire In 2023 [Member]", "documentation": "Represents expire in 2023." } } }, "auth_ref": [] }, "arch_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfWarrantOrRightExercised", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ClassOfWarrantOrRightExercised", "terseLabel": "Class of Warrant or Right, Exercised", "documentation": "The number of warrant or rights exercised during the period." } } }, "auth_ref": [] }, "arch_ClassOfWarrantOrRightAcquiredUponExercise": { "xbrltype": "sharesItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfWarrantOrRightAcquiredUponExercise", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ClassOfWarrantOrRightAcquiredUponExercise", "terseLabel": "Class Of Warrant Or Right Acquired Upon Exercise", "documentation": "The number of shares may be acquired upon exercise." } } }, "auth_ref": [] }, "arch_ExpireIn2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ExpireIn2026Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Expire In 2026 [Member]", "documentation": "Represents expire in 2026." } } }, "auth_ref": [] }, "arch_ClassOfWarrantOrRightPercentageOfSecuritiesSold": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfWarrantOrRightPercentageOfSecuritiesSold", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ClassOfWarrantOrRightPercentageOfSecuritiesSold", "terseLabel": "Class of Warrant or Right, Percentage of Securities Sold", "documentation": "Percentage of securities sold for warrant or rights." } } }, "auth_ref": [] }, "arch_ClassOfWarrantOrRightExpiredDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfWarrantOrRightExpiredDuringPeriod", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ClassOfWarrantOrRightExpiredDuringPeriod", "terseLabel": "Class of Warrant or Right, Expired During Period (in shares)", "documentation": "The number of warrants or rights expired during period." } } }, "auth_ref": [] }, "arch_ClassOfWarrantOrRightRedemptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfWarrantOrRightRedemptionPrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ClassOfWarrantOrRightRedemptionPrice", "terseLabel": "Class of Warrant or Right, Redemption Price", "documentation": "Class of Warrant or Right, Redemption Price" } } }, "auth_ref": [] }, "arch_ExpireIn2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ExpireIn2028Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Expire In 2028 [Member]", "documentation": "Represents expire in 2028." } } }, "auth_ref": [] }, "arch_ClassOfWarrantOrRightWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfWarrantOrRightWarrantsExercised", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ClassOfWarrantOrRightWarrantsExercised", "terseLabel": "Class of Warrant or Right, Warrants Exercised", "documentation": "The number of warrants exercised during the period." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "arch_ClassOfWarrantsAndRightsRequiredCashPurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClassOfWarrantsAndRightsRequiredCashPurchasePrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ClassOfWarrantsAndRightsRequiredCashPurchasePrice", "terseLabel": "Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)", "documentation": "The potentially required cash purchase price for warrants or rights." } } }, "auth_ref": [] }, "arch_FairValueAdjustmentOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "FairValueAdjustmentOfDerivatives", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "arch_FairValueAdjustmentOfDerivatives", "terseLabel": "Fair Value Adjustment of Derivatives", "negatedLabel": "Expiration of derivative liability", "documentation": "Amount of expense (income) related to adjustment to fair value of derivatives." } } }, "auth_ref": [] }, "arch_ClearingExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ClearingExpensesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Clearing Expenses [Member]", "documentation": "Related to clearing expenses." } } }, "auth_ref": [] }, "arch_ExtinguishmentOfDerivativeLiabilitiesForWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ExtinguishmentOfDerivativeLiabilitiesForWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Extinguishment of Derivative Liabilities for Warrants [Member]", "documentation": "Relating to the extinguishment of derivative liabilities for warrants." } } }, "auth_ref": [] }, "arch_FeesAndExpensesOfLegalCounselAndOtherOutofpocketExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "FeesAndExpensesOfLegalCounselAndOtherOutofpocketExpensesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Fees and Expenses of Legal Counsel and Other Out-of-pocket Expenses [Member]", "documentation": "Related to expenses." } } }, "auth_ref": [] }, "arch_FairValueOfWarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "FairValueOfWarrantsIssued", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants issued - second close", "documentation": "Amount of fair value of warrants issued." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "negatedLabel": "Adjustments to estimated fair value", "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r358", "r359" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r49", "r50", "r287" ] }, "arch_CommonStockPurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "CommonStockPurchasePrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_CommonStockPurchasePrice", "terseLabel": "Common Stock, Purchase Price", "documentation": "Represents the common stock purchase price." } } }, "auth_ref": [] }, "arch_ProceedsFromConvertibleNotesWarrantsAndCommonStockNetOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ProceedsFromConvertibleNotesWarrantsAndCommonStockNetOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds received from senior secured convertible notes", "documentation": "Cash inflow from convertible notes, warrants, and common stock net of financing costs." } } }, "auth_ref": [] }, "arch_October2019RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "October2019RegisteredDirectOfferingMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "October 2019 Registered Direct Offering [Member]", "documentation": "Related to October 2019 registered direct offering." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfWarrants", "terseLabel": "Long-Term Debt, Total", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r1" ] }, "arch_October2019PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "October2019PlacementAgentWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "October 2019 Placement Agent Warrants [Member]", "documentation": "Related to the October 2019 placement agent warrant." } } }, "auth_ref": [] }, "arch_NumberOfAccreditedInvestors": { "xbrltype": "integerItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "NumberOfAccreditedInvestors", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_NumberOfAccreditedInvestors", "terseLabel": "Number Of Accredited Investors", "documentation": "The total number of accredited investors." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r47" ] }, "arch_OtherNonoperatingIncomeLossDebtForgivenessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "OtherNonoperatingIncomeLossDebtForgivenessAmount", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_OtherNonoperatingIncomeLossDebtForgivenessAmount", "terseLabel": "Other Nonoperating Income (Loss) Debt Forgiveness Amount", "documentation": "Amount of income (expense) related to nonoperating activities from debt forgiveness, classified as other." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r101", "r126", "r127", "r128" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfFinancingCosts", "terseLabel": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r27" ] }, "arch_OperatingLeaseMonthlyRentPaymentObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "OperatingLeaseMonthlyRentPaymentObligation", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_OperatingLeaseMonthlyRentPaymentObligation", "terseLabel": "Operating Lease, Monthly Rent Payment Obligation", "documentation": "Represents monthly rent payment obligation for operating lease." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property, and equipment, Estimated Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "arch_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "arch_statement-statement-note-8-derivative-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-8-derivative-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Derivative Liabilities" } } }, "auth_ref": [] }, "arch_statement-statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details", "lang": { "en-us": { "role": { "label": "Note 8 - Derivative Liabilities - Fair Value of Derivative Liability (Details)" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r6" ] }, "arch_statement-statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 8 - Derivative Liabilities - Derivative Liability Value Assumptions (Details)" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Expected income tax (benefit) at federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r159", "r327", "r337" ] }, "arch_PrivatePlacementNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PrivatePlacementNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Private Placement Notes [Member]", "documentation": "Represents private placement notes." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r102" ] }, "arch_PrefundedWarrantsParticipatingInUplistTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PrefundedWarrantsParticipatingInUplistTransactionMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrants Participating in Uplist Transaction [Member]", "documentation": "Prefunded Warrants Participating in Uplist Transaction" } } }, "auth_ref": [] }, "arch_InConnectionWithNearTermCapitalRaiseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "InConnectionWithNearTermCapitalRaiseMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "In Connection With Near Term Capital Raise [Member]", "documentation": "Represents In Connection With Near Term Capital Raise." } } }, "auth_ref": [] }, "arch_OwnershipLimitation": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "OwnershipLimitation", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_OwnershipLimitation", "terseLabel": "Ownership Limitation", "documentation": "Represents ownership limitation." } } }, "auth_ref": [] }, "arch_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "IncreaseDecreaseInAccruedExpensesAndOtherLiabilities", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Accrued expenses and other liabilities", "documentation": "The amount of increase (decrease) in accrued expenses and other liabilities." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other." } } }, "auth_ref": [ "r51", "r52", "r602" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Research and development credit carryforwards", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r51", "r52", "r602" ] }, "arch_IncreaseDecreaseRateOfPercentageAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "IncreaseDecreaseRateOfPercentageAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Increase/(Decrease) due to:" } } }, "auth_ref": [] }, "arch_IncreaseInAggregateNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "IncreaseInAggregateNumberOfShares", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_IncreaseInAggregateNumberOfShares", "terseLabel": "Increase In Aggregate Number Of Shares", "documentation": "The amount of increase, in aggregate, of the number of shares." } } }, "auth_ref": [] }, "arch_WarrantSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "WarrantSharesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Warrant Shares [Member]", "documentation": "Represents warrant shares." } } }, "auth_ref": [] }, "arch_ParticipatingInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ParticipatingInvestorsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Participating Investors [Member]", "documentation": "Related to participating investors." } } }, "auth_ref": [] }, "arch_InducementShares2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "InducementShares2022Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Inducement Shares 2022 [Member]", "documentation": "Represents inducement shares 2022." } } }, "auth_ref": [] }, "arch_statement-statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details)" } } }, "auth_ref": [] }, "arch_WarrantsExchangedForCommonStockNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "WarrantsExchangedForCommonStockNoncash", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Exchange of Series G and Series H warrants for common stock", "documentation": "Amount of warrants exchanged for common stock in noncash transaction." } } }, "auth_ref": [] }, "arch_PaymentsOfShareholderAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PaymentsOfShareholderAdvances", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_PaymentsOfShareholderAdvances", "terseLabel": "Payments of Shareholder Advances", "documentation": "Amount of cash outflow for shareholder advances." } } }, "auth_ref": [] }, "arch_WarrantsAndRightsPercentOfStockOustandingCallable": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "WarrantsAndRightsPercentOfStockOustandingCallable", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_WarrantsAndRightsPercentOfStockOustandingCallable", "terseLabel": "Warrants and Rights, Percent of Stock Oustanding Callable", "documentation": "The percent of stock outstanding that is callable by warrants and rights." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "arch_PaycheckProtectionProgramLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PaycheckProtectionProgramLoanMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program Loan [Member]", "documentation": "Related to Paycheck Protection Program loan." } } }, "auth_ref": [] }, "arch_InsurancePremiumFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "InsurancePremiumFinancingMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A" ], "lang": { "en-us": { "role": { "label": "Insurance Premium Financing [Member]", "documentation": "Represents insurance premium financing." } } }, "auth_ref": [] }, "arch_statement-statement-note-7-derivative-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-7-derivative-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Derivative Liabilities" } } }, "auth_ref": [] }, "arch_WarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "WarrantsIssued", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Fair value of 2022 Warrants issued (see Note 10)", "documentation": "Represents warrant issued" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLifeInsurance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLifeInsurance", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Key man life insurance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to life insurance expense." } } }, "auth_ref": [ "r600", "r603" ] }, "arch_PercentageOfCommonStockNeedsForActionByWrittenConsent": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PercentageOfCommonStockNeedsForActionByWrittenConsent", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_PercentageOfCommonStockNeedsForActionByWrittenConsent", "terseLabel": "Percentage of Common Stock Needs for Action by Written Consent", "documentation": "Percentage of Common Stock Needs for Action by Written Consent" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r208", "r209", "r210", "r211", "r384", "r385" ] }, "arch_InterestPayableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "InterestPayableNoncurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables, classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfCommonStock", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "arch_PayrollProtectionProgramLoanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PayrollProtectionProgramLoanTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan" ], "lang": { "en-us": { "role": { "label": "Payroll Protection Program Loan [Text Block]", "documentation": "The entire disclosure of payroll protection program loan." } } }, "auth_ref": [] }, "arch_statement-statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "lang": { "en-us": { "role": { "label": "Note 7 - Derivative Liabilities - Fair Value of Derivative Liability (Details)" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "PPP Loan Forgiveness", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r600", "r603" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r36" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "R&D, taken as a credit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r600", "r603" ] }, "arch_PercentageOfCommonStockThatShallConstituteAQuorumAtStockholdersMeeting": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PercentageOfCommonStockThatShallConstituteAQuorumAtStockholdersMeeting", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_PercentageOfCommonStockThatShallConstituteAQuorumAtStockholdersMeeting", "terseLabel": "Percentage of Common Stock That Shall Constitute a Quorum at Stockholders Meeting", "documentation": "Percentage of Common Stock That Shall Constitute a Quorum at Stockholders Meeting" } } }, "auth_ref": [] }, "arch_statement-statement-note-10-2022-convertible-note-offering-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-10-2022-convertible-note-offering-tables", "lang": { "en-us": { "role": { "label": "Note 10 - 2022 Convertible Note Offering" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par Value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r406" ] }, "arch_PercentageOfFeeOnGrossProceedsOfWarrants": { "xbrltype": "pureItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PercentageOfFeeOnGrossProceedsOfWarrants", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_PercentageOfFeeOnGrossProceedsOfWarrants", "terseLabel": "Percentage of Fee on Gross Proceeds of Warrants", "documentation": "Percentage of fee on gross Proceeds of warrants." } } }, "auth_ref": [] }, "arch_statement-statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "lang": { "en-us": { "role": { "label": "Note 11 - 2022 Convertible Note Offering and Second Notes Offering - Summary of Valuation Assumptions for Warrants (Details)" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r38", "r39" ] }, "arch_PercentageOfGrossProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PercentageOfGrossProceedsFromIssuanceOfPrivatePlacement", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_PercentageOfGrossProceedsFromIssuanceOfPrivatePlacement", "terseLabel": "Percentage of Gross Proceeds from Issuance of Private Placement", "documentation": "Represents percentage of gross proceeds from issuance of private placement." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "terseLabel": "Stock Based Compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r600", "r603" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Stock based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r52", "r602" ] }, "arch_InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "InvestorWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "Investor Warrants [Member]", "documentation": "Represents investor warrants." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r565", "r609" ] }, "arch_PercentageOfPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PercentageOfPrincipalAmount", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_PercentageOfPrincipalAmount", "terseLabel": "Percentage of Principal Amount", "documentation": "Represents percentage of principal amount." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r600", "r603" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "arch_statement-statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables", "lang": { "en-us": { "role": { "label": "Note 11 - 2022 Convertible Note Offering, Second Notes Offering, and Third Notes Offering" } } }, "auth_ref": [] }, "arch_statement-statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "lang": { "en-us": { "role": { "label": "Note 11 - 2022 Convertible Note Offering - Summary of Valuation Assumptions for Warrants (Details)" } } }, "auth_ref": [] }, "arch_PercentageOfWarrantsPerUnit": { "xbrltype": "pureItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PercentageOfWarrantsPerUnit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_PercentageOfWarrantsPerUnit", "terseLabel": "Percentage of Warrants Per Unit", "documentation": "The percentage of warrants per unit." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r52", "r602" ] }, "arch_IssuanceOfRestrictedStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "IssuanceOfRestrictedStock", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted stock", "documentation": "The fair value of Restricted stock issued in noncash financing activities." } } }, "auth_ref": [] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r286", "r288", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r129", "r138", "r139", "r140", "r158", "r178", "r179", "r181", "r183", "r186", "r187", "r203", "r220", "r222", "r223", "r224", "r227", "r228", "r260", "r261", "r264", "r267", "r273", "r361", "r406", "r407", "r408", "r409", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r442", "r464", "r483", "r503", "r504", "r505", "r506", "r507", "r547", "r556", "r564" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "State income taxes \u2013 net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r600", "r603" ] }, "arch_statement-statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Computation of Provision (benefits) Income Taxes from Statutory Federal Income Tax Rate (Details)" } } }, "auth_ref": [] }, "arch_statement-statement-note-12-income-taxes-net-deferred-tax-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-12-income-taxes-net-deferred-tax-assets-details", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Net Deferred Tax Assets (Details)" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "arch_PlacementAgent2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PlacementAgent2022Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Placement Agent 2022 [Member]", "documentation": "Represents 2022 placement agent." } } }, "auth_ref": [] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r288", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315" ] }, "arch_statement-statement-note-12-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-12-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r67", "r325", "r618" ] }, "arch_IssuanceOrSaleOfEquityNumberOfUnits": { "xbrltype": "integerItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "IssuanceOrSaleOfEquityNumberOfUnits", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_IssuanceOrSaleOfEquityNumberOfUnits", "terseLabel": "Issuance or Sale of Equity, Number of Units", "documentation": "Represents issuance or sale of equity." } } }, "auth_ref": [] }, "arch_PermanentDifferencesOnPercentageAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PermanentDifferencesOnPercentageAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Permanent Differences:" } } }, "auth_ref": [] }, "arch_statement-statement-note-14-stockbased-compensation-restricted-stock-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-14-stockbased-compensation-restricted-stock-activity-details", "lang": { "en-us": { "role": { "label": "Note 14 - Stock-based Compensation - Restricted Stock Activity (Details)" } } }, "auth_ref": [] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r286", "r288", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315" ] }, "arch_IssuanceOfRestrictedStockForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "IssuanceOfRestrictedStockForServices", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted stock in consideration for services performed", "documentation": "Represents issuance of restricted stock for services." } } }, "auth_ref": [] }, "arch_statement-statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "lang": { "en-us": { "role": { "label": "Note 14 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details)" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfPrivatePlacement", "terseLabel": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r1" ] }, "arch_statement-statement-note-14-stockbased-compensation-stock-compensation-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-14-stockbased-compensation-stock-compensation-activity-details", "lang": { "en-us": { "role": { "label": "Note 14 - Stock-based Compensation - Stock Compensation Activity (Details)" } } }, "auth_ref": [] }, "arch_LongTermPromissoryConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "LongTermPromissoryConvertibleNote", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Series 1 convertible notes", "documentation": "Represents the amount of long term promissory convertible note." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total costs and expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r89" ] }, "arch_statement-statement-note-14-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-14-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Stock-based Compensation" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4" ] }, "arch_PlacementAgent2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PlacementAgent2WarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Placement Agent 2 Warrants [Member]", "documentation": "Related to placement agent 2 warrants." } } }, "auth_ref": [] }, "arch_MITLicensingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "MITLicensingAgreementMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "M I T Licensing Agreement [Member]", "documentation": "Represents MIT Licensing Agreement." } } }, "auth_ref": [] }, "arch_statement-statement-note-3-property-and-equipment-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-3-property-and-equipment-10q-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Property and Equipment (10Q)" } } }, "auth_ref": [] }, "arch_PlacementAgent2022SecondNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PlacementAgent2022SecondNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Placement Agent 2022, Second Notes [Member]", "documentation": "Represents Placement Agent 2022, Second Notes" } } }, "auth_ref": [] }, "arch_statement-statement-note-3-property-and-equipment-property-and-equipment-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-3-property-and-equipment-property-and-equipment-10q-details", "lang": { "en-us": { "role": { "label": "Note 3 - Property and Equipment - Property and Equipment (10Q) (Details)" } } }, "auth_ref": [] }, "arch_MaximumSpecifiedPercentageUnlessAgreedByHolder": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "MaximumSpecifiedPercentageUnlessAgreedByHolder", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_MaximumSpecifiedPercentageUnlessAgreedByHolder", "terseLabel": "Maximum Specified Percentage Unless Agreed by Holder", "documentation": "Maximum Specified Percentage Unless Agreed by Holder" } } }, "auth_ref": [] }, "arch_statement-statement-note-3-property-and-equipment-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-3-property-and-equipment-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 3 - Property and Equipment - Property and Equipment (Details)" } } }, "auth_ref": [] }, "arch_MaximumSpecifiedPercentageUnlessAgreedByCompany": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "MaximumSpecifiedPercentageUnlessAgreedByCompany", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_MaximumSpecifiedPercentageUnlessAgreedByCompany", "terseLabel": "Maximum Specified Percentage Unless Agreed by Company", "documentation": "Maximum Specified Percentage Unless Agreed by Company" } } }, "auth_ref": [] }, "arch_statement-statement-note-3-property-and-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-3-property-and-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Property and Equipment" } } }, "auth_ref": [] }, "arch_statement-statement-note-4-inventories-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-4-inventories-10q-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories (10Q)" } } }, "auth_ref": [] }, "arch_NonEmployeeRestrictedSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "NonEmployeeRestrictedSharesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Non Employee Restricted Shares [Member]", "documentation": "Represents non-employee restricted shares." } } }, "auth_ref": [] }, "arch_PlacementAgentWarrant2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PlacementAgentWarrant2022Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Placement Agent Warrant 2022 [Member]", "documentation": "Represents 2022 placement agent warrants." } } }, "auth_ref": [] }, "arch_statement-statement-note-4-inventories-inventories-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-4-inventories-inventories-10q-details", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories - Inventories (10Q) (Details)" } } }, "auth_ref": [] }, "arch_NonaccountableExpenseFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "NonaccountableExpenseFeeMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Non-accountable Expense Fee [Member]", "documentation": "Related to non-accountable expense fee." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "arch_statement-statement-note-4-inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-4-inventories-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories" } } }, "auth_ref": [] }, "arch_statement-statement-note-5-inventories-inventories-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-5-inventories-inventories-details", "lang": { "en-us": { "role": { "label": "Note 5 - Inventories - Inventories (Details)" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r27" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebt", "terseLabel": "Long-Term Debt, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r13", "r120", "r242", "r257", "r521", "r522", "r621" ] }, "arch_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants [Member]", "documentation": "Represents placement agent warrants." } } }, "auth_ref": [] }, "arch_Notes2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "Notes2022Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Notes 2022 [Member]", "documentation": "Represents 2022 notes." } } }, "auth_ref": [] }, "arch_statement-statement-note-6-stockbased-compensation-restricted-stock-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-6-stockbased-compensation-restricted-stock-activity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stock-based Compensation - Restricted Stock Activity (Details)" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Deferred tax asset valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r332" ] }, "arch_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "arch_statement-statement-note-6-stockbased-compensation-stock-compensation-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-6-stockbased-compensation-stock-compensation-activity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stock-based Compensation - Stock Compensation Activity (Details)" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r125", "r391", "r423", "r450", "r531", "r543", "r550" ] }, "arch_PlacementAgentsFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PlacementAgentsFees", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_PlacementAgentsFees", "terseLabel": "Placement Agents Fees", "documentation": "Amount of placement agents fees during a period of time." } } }, "auth_ref": [] }, "arch_statement-statement-note-6-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-6-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Stock-based Compensation" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "arch_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "PrefundedWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrants [Member]", "documentation": "Represents the prefunded warrants." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year." } } }, "auth_ref": [ "r48" ] }, "arch_statement-statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "statement-statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 7 - Derivative Liabilities - Derivative Liability Value Assumptions (Details)" } } }, "auth_ref": [] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r59", "r116" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16", "r531" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeLiabilities", "terseLabel": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r143", "r144", "r360", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r456", "r458", "r459", "r494", "r495", "r496", "r498", "r499", "r500", "r501", "r515", "r624" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details" ], "lang": { "en-us": { "role": { "label": "Finished Goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r551" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfDebt", "terseLabel": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r555" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r87", "r97", "r122", "r131", "r145", "r146", "r149", "r158", "r166", "r168", "r169", "r170", "r171", "r174", "r175", "r180", "r188", "r193", "r197", "r199", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r354", "r361", "r397", "r463", "r481", "r482", "r518", "r541", "r569" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "terseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r78" ] }, "us-gaap_OtherNoncashIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpenseAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Other (expense) income:" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r243", "r277", "r278", "r279", "r280", "r281", "r282", "r355", "r378", "r379", "r380", "r521", "r522", "r526", "r527", "r528" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Derivative liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r143" ] }, "us-gaap_NatureOfExpenseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfExpenseAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Nature of Expense [Axis]", "documentation": "Information by type of cost or expense." } } }, "auth_ref": [ "r37" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value, 800,000,000 shares authorized as of September 30, 2022 and 2021, 249,886,370 and 237,169,770 shares issued as of September 30, 2022 and 2021, and 249,936,370 and 236,719,770 outstanding as of September 30, 2022 and 2021", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r78", "r392", "r531" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r78", "r442" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding, Ending Balance (in shares)", "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r78", "r442", "r461", "r626", "r627" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details" ], "lang": { "en-us": { "role": { "label": "Inventory", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r141", "r512", "r531" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Conversion of shareholder advance into unsecured convertible note", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r31", "r33" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance at September 30, 2021 (in shares)", "periodEndLabel": "Balance at September 30, 2022 (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Current portion of derivative liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r112" ] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r31", "r33" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r111" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsGross", "terseLabel": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r62" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r31", "r33" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r15", "r84", "r85", "r86" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r68", "r98", "r99" ] }, "arch_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Proceeds from issued common stock and warrants, net of financing costs", "documentation": "The cash inflow from the issuance of common stock and warrants net of financing costs." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r94" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r544" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r110" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r152", "r168", "r169", "r170", "r171", "r172", "r177", "r178", "r181", "r182", "r183", "r184", "r353", "r354", "r386", "r398", "r516" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r102" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryWorkInProcess", "terseLabel": "Goods-in-process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r552" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "arch_ThresholdOfPublicOfferingPricePerShareToTriggerIssuanceOfAdditionalSecurities": { "xbrltype": "perShareItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ThresholdOfPublicOfferingPricePerShareToTriggerIssuanceOfAdditionalSecurities", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ThresholdOfPublicOfferingPricePerShareToTriggerIssuanceOfAdditionalSecurities", "terseLabel": "Threshold of Public Offering Price Per Share to Trigger Issuance of Additional Securities", "documentation": "Threshold of Public Offering Price Per Share to Trigger Issuance of Additional Securities" } } }, "auth_ref": [] }, "arch_UnpaidIssuanceCostsInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "UnpaidIssuanceCostsInAccountsPayable", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Unpaid issuance costs in accounts Payable", "documentation": "Amount of unpaid issuance costs in accounts payable." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "negatedLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r306" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r276", "r283", "r312", "r313", "r314", "r381", "r382", "r399", "r432", "r433", "r489", "r490", "r491", "r492", "r502", "r510", "r511", "r519", "r525", "r529", "r532", "r535", "r567", "r571", "r613", "r614", "r615", "r616", "r617" ] }, "arch_SeriesFWarrantDerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesFWarrantDerivativeMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Series F Warrant Derivative [Member]", "documentation": "Related to Series F Warrant derivative liability." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r605" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r79" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "arch_Warrant2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "Warrant2022Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Warrant 2022 [Member]", "documentation": "Represents 2022 warrants." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-16-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A", "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r163", "r164", "r165", "r185", "r383", "r405", "r424", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r445", "r446", "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r456", "r457", "r458", "r459", "r460", "r462", "r465", "r466", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r483", "r536" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "arch_UplistTransactionPurchasePriceRateOverPricePaidByInvestor": { "xbrltype": "pureItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "UplistTransactionPurchasePriceRateOverPricePaidByInvestor", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_UplistTransactionPurchasePriceRateOverPricePaidByInvestor", "terseLabel": "Uplist Transaction, Purchase Price Rate Over Price Paid by Investor", "documentation": "Uplist Transaction, Purchase Price Rate Over Price Paid by Investor." } } }, "auth_ref": [] }, "arch_ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross", "terseLabel": "Proceeds from Issuance of Convertible Notes, Common Stock and Warrants, Gross", "documentation": "Represents gross proceeds from issuance of convertible notes, common stock and warrants." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r283", "r382", "r399", "r432", "r433", "r489", "r490", "r491", "r492", "r502", "r510", "r511", "r519", "r525", "r529", "r532", "r571", "r612", "r613", "r614", "r615", "r616", "r617" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity (deficit):" } } }, "auth_ref": [] }, "arch_ProceedsFromShareholderAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ProceedsFromShareholderAdvances", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from shareholder advances", "terseLabel": "Proceeds from Shareholder Advances", "documentation": "Amount of cash inflow from shareholder advances." } } }, "auth_ref": [] }, "arch_StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of financing costs", "documentation": "Equity impact of the value of new stock and warrants issued during the period, net of financing costs." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r605" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r276", "r283", "r312", "r313", "r314", "r381", "r382", "r399", "r432", "r433", "r489", "r490", "r491", "r492", "r502", "r510", "r511", "r519", "r525", "r529", "r532", "r535", "r567", "r571", "r613", "r614", "r615", "r616", "r617" ] }, "arch_StockAndWarrantsIssuedDuringPeriodSharesNewIssuesNetOfFinancingCosts": { "xbrltype": "sharesItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "StockAndWarrantsIssuedDuringPeriodSharesNewIssuesNetOfFinancingCosts", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of financing costs (in shares)", "documentation": "Number of stock and warrants issued during the period." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r274" ] }, "arch_ReclassificationOfExchangedNotesIncludedInNotesPayableToUnsecuredConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ReclassificationOfExchangedNotesIncludedInNotesPayableToUnsecuredConvertibleNotes", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ReclassificationOfExchangedNotesIncludedInNotesPayableToUnsecuredConvertibleNotes", "terseLabel": "Reclassification of Exchanged Notes Included in Notes Payable to Unsecured Convertible Notes", "documentation": "Represents Reclassification of Exchanged Notes Included in Notes Payable to Unsecured Convertible Notes." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r605" ] }, "arch_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Exchange of warrants into common stock (in shares)", "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised", "documentation": "The number of shares issued during the period for warrant exercises." } } }, "auth_ref": [] }, "arch_ProceedsFromSubscribedUnissuedCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ProceedsFromSubscribedUnissuedCommonStockAndWarrants", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ProceedsFromSubscribedUnissuedCommonStockAndWarrants", "terseLabel": "Proceeds from Subscribed, Unissued Common Stock and Warrants", "documentation": "Proceeds from subscribed but unissued common stock and warrants during the period." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r283", "r382", "r399", "r432", "r433", "r489", "r490", "r491", "r492", "r502", "r510", "r511", "r519", "r525", "r529", "r532", "r571", "r612", "r613", "r614", "r615", "r616", "r617" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r106", "r157", "r259", "r261", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r275", "r351", "r487", "r488", "r508" ] }, "arch_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3" ], "lang": { "en-us": { "role": { "label": "Exchange of warrants into common stock", "documentation": "Value of stock issued during the period for warrants exercised." } } }, "auth_ref": [] }, "arch_StockholdersEquityNoteDirectOffering2019OctoberTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "StockholdersEquityNoteDirectOffering2019OctoberTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note Direct Offering 2019 October [Text Block]", "documentation": "The entire disclosure of the October 2019 registered direct offering." } } }, "auth_ref": [] }, "arch_RegisteredDirectOffering2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "RegisteredDirectOffering2018Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Registered Direct Offering 2018 [Member]", "documentation": "The 2018 registered direct offering." } } }, "auth_ref": [] }, "arch_StockholdersEquityNoteDirectOfferingsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "StockholdersEquityNoteDirectOfferingsTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Direct Offerings [Text Block]", "documentation": "The entire disclosure for registered direct offerings." } } }, "auth_ref": [] }, "arch_RegisteredDirectOffering2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "RegisteredDirectOffering2019Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Registered Direct Offering 2019 [Member]", "documentation": "Represents 2019 registered direct offering." } } }, "auth_ref": [] }, "arch_The2013PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "The2013PlanMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "The 2013 Plan [Member]", "documentation": "Related to the 2013 plan." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r160", "r161", "r233", "r262", "r374", "r513", "r515" ] }, "arch_RegisteredDirectOfferingOctober2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "RegisteredDirectOfferingOctober2019Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Registered Direct Offering October 2019 [Member]", "documentation": "Represents the October 2019 registered direct offering." } } }, "auth_ref": [] }, "arch_ReimbursementOfNonaccountableBankingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ReimbursementOfNonaccountableBankingFees", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ReimbursementOfNonaccountableBankingFees", "terseLabel": "Reimbursement of Non-accountable Banking Fees", "documentation": "Represents reimbursement of non-accountable banking fees." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "arch_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ReverseStockSplitMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r546" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "arch_The2017SPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "The2017SPAMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2017 SPA [Member]", "documentation": "Related to the 2017 SPA." } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r330" ] }, "arch_SecondNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SecondNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Second Notes [Member]", "documentation": "Represents second notes." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r160", "r161", "r233", "r262", "r374", "r514", "r515" ] }, "arch_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r129", "r138", "r139", "r140", "r158", "r178", "r179", "r181", "r183", "r186", "r187", "r203", "r220", "r222", "r223", "r224", "r227", "r228", "r260", "r261", "r264", "r267", "r273", "r361", "r406", "r407", "r408", "r409", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r442", "r464", "r483", "r503", "r504", "r505", "r506", "r507", "r547", "r556", "r564" ] }, "arch_The2018SPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "The2018SPAMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2018 SPA [Member]", "documentation": "Related to the 2018 SPA." } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r113" ] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Measurement Input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": [ "r357" ] }, "arch_SeriesDWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesDWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Series D Warrants [Member]", "documentation": "Related to Series D Warrants." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInterestPayableNet", "terseLabel": "Accrued interest", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r2" ] }, "arch_SecondWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SecondWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Second Warrants [Member]", "documentation": "Represents the second warrants." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r544" ] }, "arch_SecondPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SecondPlacementAgentWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Second Placement Agent Warrants [Member]", "documentation": "Represents the second placement agent warrants." } } }, "auth_ref": [] }, "arch_The2019SPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "The2019SPAMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2019 SPA [Member]", "documentation": "Related to the 2019 SPA." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 deficit", "periodStartLabel": "Balance at September 30, 2021", "periodEndLabel": "Balance at September 30, 2022", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r78", "r81", "r82", "r100", "r444", "r461", "r485", "r486", "r531", "r543", "r558", "r566", "r607", "r626" ] }, "arch_UnsecuredConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "UnsecuredConvertibleNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Unsecured Convertible Notes [Member]", "documentation": "Relating to unsecured convertible notes." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventory", "negatedTerseLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r2" ] }, "arch_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Represents securities purchase agreement." } } }, "auth_ref": [] }, "arch_The2022NotesAndSecondNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "The2022NotesAndSecondNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2022 Notes and Second Notes [Member]", "documentation": "Represents the 2022 notes and second notes." } } }, "auth_ref": [] }, "arch_SecuritiesPurchaseAgreementCashPlacementFee": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SecuritiesPurchaseAgreementCashPlacementFee", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_SecuritiesPurchaseAgreementCashPlacementFee", "terseLabel": "Securities Purchase Agreement, Cash Placement Fee", "documentation": "The cash placement fee under a securities purchase agreement." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r544" ] }, "arch_The2021RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "The2021RegisteredDirectOfferingMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2021 Registered Direct Offering [Member]", "documentation": "Related to the 2021 registered direct offering." } } }, "auth_ref": [] }, "arch_SecuritiesPurchaseAgreementPotentialFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SecuritiesPurchaseAgreementPotentialFees", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_SecuritiesPurchaseAgreementPotentialFees", "terseLabel": "Securities Purchase Agreement, Potential Fees", "documentation": "The amount of potential fees under securities purchase agreement." } } }, "auth_ref": [] }, "arch_The2023OmnibusEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "The2023OmnibusEquityIncentivePlanMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2023 Omnibus Equity Incentive Plan [Member]", "documentation": "2023 Omnibus Equity Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested and expected to vest, weighted average remaining contractual term (Year)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r310" ] }, "arch_SeniorSecuredConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeniorSecuredConvertibleNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Senior Secured Convertible Notes [Member]", "documentation": "Represents senior secured convertible notes." } } }, "auth_ref": [] }, "arch_The2023SPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "The2023SPAMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2023 SPA [Member]", "documentation": "Represents the 2023 SPA." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r544" ] }, "arch_SeniorSecuredConvertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeniorSecuredConvertiblePromissoryNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Senior Secured Convertible Promissory Notes [Member]", "documentation": "Senior Secured Convertible Promissory Notes." } } }, "auth_ref": [] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Inventory obsolescence charge", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r207" ] }, "arch_Series12ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "Series12ConvertibleNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Series 1 & 2 Convertible Notes [Member]", "documentation": "Related to Series 1 & 2 Convertible Notes." } } }, "auth_ref": [] }, "us-gaap_TechnologyEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyEquipmentMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Technology Equipment [Member]", "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals." } } }, "auth_ref": [] }, "arch_ThirdInducementSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ThirdInducementSharesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Third Inducement Shares [Member]", "documentation": "Represents the third inducement shares." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r357" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r544" ] }, "arch_Series1ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "Series1ConvertibleNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Series 1 Convertible Notes [Member]", "documentation": "Related to Series 1 Convertible Notes." } } }, "auth_ref": [] }, "arch_ThirdNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ThirdNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Third Notes [Member]", "documentation": "Represents third notes." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r311" ] }, "arch_Series2ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "Series2ConvertibleNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Series 2 Convertible Notes [Member]", "documentation": "Related to Series 2 Convertible Notes." } } }, "auth_ref": [] }, "arch_SeriesDWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesDWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Series D Warrant [Member]", "documentation": "Represents series D warrant." } } }, "auth_ref": [] }, "arch_ThirdWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ThirdWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Third Warrants [Member]", "documentation": "Represents the third warrants." } } }, "auth_ref": [] }, "arch_Series2NotesConvertedToSeniorSecuredConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "Series2NotesConvertedToSeniorSecuredConvertibleNotesMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Series 2 Notes Converted to Senior Secured Convertible Notes [Member]", "documentation": "Series 2 Notes Converted to Senior Secured Convertible Notes." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r545" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r46" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r431", "r433", "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r456", "r457", "r458", "r459", "r471", "r472", "r473", "r474", "r477", "r478", "r479", "r480", "r493", "r494", "r498", "r500", "r533", "r535" ] }, "us-gaap_OtherSignificantNoncashTransactionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSignificantNoncashTransactionNameDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Significant Noncash Transaction, Name [Domain]", "documentation": "The name of other significant noncash (or part noncash) investing and financing activities required to be supplementally disclosed to enable users of the financial information to fully understand the period cash flows of the Entity in relation to the statements of financial position, income statement, and statement of changes in shareholders' equity. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "Vesting of restricted stock", "terseLabel": "Vesting of restricted stock issued", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r5", "r109" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Operating Lease, Liability, Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r372" ] }, "us-gaap_OtherSignificantNoncashTransactionsByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSignificantNoncashTransactionsByUniqueDescriptionAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Significant Noncash Transaction [Axis]", "documentation": "Information by other significant noncash transactions." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues", "terseLabel": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r77", "r78", "r109", "r406", "r483", "r504" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r306" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "Awarded (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r304" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Awarded (in dollars per share)", "negatedLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r304" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodStartLabel": "Non Vested at September 30, 2021 and 2020 (in shares)", "periodEndLabel": "Non Vested at September 30, 2022 and 2021 (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r301", "r302" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Non Vested at September 30, 2021 and 2020 (in dollars per share)", "periodEndLabel": "Non Vested at September 30, 2022 and 2021 (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r301", "r302" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r7" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r319" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r305" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r560", "r561", "r604", "r623", "r626" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "Vesting of restricted stock (in shares)", "terseLabel": "Vesting of restricted stock issued (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r5", "r77", "r78", "r109" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "negatedLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r305" ] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Accretion of discount and debt issuance costs on 2022 Notes", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r3" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r90", "r158", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r361", "r569" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Awarded, shares (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r297" ] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r104" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r2" ] }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterimPeriodCostsNotAllocableDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Interim Period, Costs Not Allocable [Domain]", "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited/Cancelled, shares (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r299" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r321", "r322", "r323", "r412", "r560", "r561", "r562", "r604", "r626" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r599" ] }, "arch_SingleInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SingleInvestorMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Single Investor [Member]", "documentation": "Represents single investor" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "Closing price per share of Common Stock (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "arch_ShortTermLoanIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ShortTermLoanIssued", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Financing of insurance premium", "documentation": "The fair value of short term loan issued in noncash investing and financing activities." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r285", "r289", "r317", "r318", "r320", "r530" ] }, "arch_SeriesFWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesFWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Series F Warrant [Member]", "documentation": "Related to Series F Warrant." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r153" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Current portion of Series 1 convertible notes", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r19" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r153" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-16-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A", "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r163", "r164", "r165", "r185", "r383", "r405", "r424", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r445", "r446", "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r456", "r457", "r458", "r459", "r460", "r462", "r465", "r466", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r483", "r536" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r95", "r96", "r97" ] }, "arch_SeriesGWarrantDerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesGWarrantDerivativeMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Series G Warrant Derivative [Member]", "documentation": "Related to Series G Warrant derivative." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r316", "r324" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r117", "r137", "r158", "r188", "r194", "r198", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r341", "r343", "r361", "r389", "r455", "r531", "r543", "r569", "r570", "r610" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Change in Valuation Allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r600", "r603" ] }, "us-gaap_AccruedRentCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRentCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedRentCurrentAndNoncurrent", "terseLabel": "Accrued Rent", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements." } } }, "auth_ref": [ "r74", "r76", "r119" ] }, "arch_SeriesGWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesGWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Series G Warrant [Member]", "documentation": "Related to Series G Warrant." } } }, "auth_ref": [] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Senior secured convertible notes, net of discount and issuance costs", "terseLabel": "Convertible Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r23" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r544" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r25", "r130", "r147", "r148", "r149", "r163", "r164", "r165", "r167", "r173", "r175", "r185", "r204", "r205", "r275", "r321", "r322", "r323", "r334", "r335", "r345", "r346", "r347", "r348", "r349", "r350", "r352", "r362", "r363", "r364", "r365", "r366", "r367", "r373", "r400", "r401", "r402", "r412", "r483" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r243", "r277", "r278", "r279", "r280", "r281", "r282", "r355", "r380", "r521", "r522", "r526", "r527", "r528" ] }, "arch_SeriesHWarrantDerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesHWarrantDerivativeMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Series H Warrant Derivative [Member]", "documentation": "Related to Series H Warrant derivative." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r130", "r163", "r164", "r165", "r167", "r173", "r175", "r204", "r205", "r321", "r322", "r323", "r334", "r335", "r345", "r347", "r348", "r350", "r352", "r400", "r402", "r412", "r626" ] }, "arch_SeriesHWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesHWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details" ], "lang": { "en-us": { "role": { "label": "Series H Warrant [Member]", "documentation": "Related to Series H Warrant." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-16-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A", "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfDerivatives", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Gain on extinguishment of derivative liabilities", "terseLabel": "Gain (Loss) on Sale of Derivatives", "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings." } } }, "auth_ref": [ "r3", "r123", "r471", "r472", "r473", "r474" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockSharesAuthorized", "terseLabel": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r77", "r442" ] }, "arch_SeriesIWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesIWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Series I Warrant [Member]", "documentation": "Related to Series I warrant." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement--note-6-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets-parentheticals14DFA13C-C5A5-4A60-A65B-77CD8E455C24", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-basis-of-presentation-and-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business", "http://www.archtherapeutics.com/20220930/role/statement-note-1-description-of-business-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-and-second-notes-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-summary-of-valuation-assumptions-for-warrants-details", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-net-deferred-tax-assets-details", "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan", "http://www.archtherapeutics.com/20220930/role/statement-note-13-payroll-protection-program-loan-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-13-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-restricted-stock-weighted-average-grant-date-fair-value-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies", "http://www.archtherapeutics.com/20220930/role/statement-note-15-commitments-and-contingencies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events", "http://www.archtherapeutics.com/20220930/role/statement-note-15-subsequent-events-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-16-risks-and-uncertainties-covid19-and-geopolitical-conflicts", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-10q-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-inventories-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-4-inventories-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financing-details-textual24A8C8DA-32FA-4B78-B6C6-C5C9EA5DA0C9", "http://www.archtherapeutics.com/20220930/role/statement-note-5-insurance-premium-financingAF17A54B-59FA-4DD7-A3EE-937FDECFC24A", "http://www.archtherapeutics.com/20220930/role/statement-note-5-inventories-inventories-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-restricted-stock-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-7-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-derivative-liability-value-assumptions-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-fair-value-of-derivative-liability-details", "http://www.archtherapeutics.com/20220930/role/statement-note-8-derivative-liabilities-tables", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "arch_SeriesIAndPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesIAndPlacementAgentWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Series I and Placement Agent Warrants [Member]", "documentation": "Represents Series I and placement agent warrants." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross, Total", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r102", "r134", "r396" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-10q-details", "http://www.archtherapeutics.com/20220930/role/statement-note-3-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net, Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r388", "r396", "r531" ] }, "arch_SeriesJWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesJWarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Series J Warrants [Member]", "documentation": "Related to Series J Warrants." } } }, "auth_ref": [] }, "arch_ShelfRegistrationStatementMaximumAmountAuthorized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ShelfRegistrationStatementMaximumAmountAuthorized", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-7-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_ShelfRegistrationStatementMaximumAmountAuthorized", "terseLabel": "Shelf Registration Statement, Maximum Amount Authorized", "documentation": "The maximum amount authorized under the shelf registration statement at the reporting date." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited278F66D9-DE78-40CB-A225-99BEFEEEFF89", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited3F853D83-EF06-49CE-9CE1-373E40D2C56C", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited4B06FC41-D0C0-4356-AA0F-F7EF8F2D4A9F", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unaudited764C407B-6C8F-4E94-82F9-AD14D58BDAF3", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-unauditedB1CC72E6-0744-4BE2-A712-3EB4315222DC", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.archtherapeutics.com/20220930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r130", "r147", "r148", "r149", "r163", "r164", "r165", "r167", "r173", "r175", "r185", "r204", "r205", "r275", "r321", "r322", "r323", "r334", "r335", "r345", "r346", "r347", "r348", "r349", "r350", "r352", "r362", "r363", "r364", "r365", "r366", "r367", "r373", "r400", "r401", "r402", "r412", "r483" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r544" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2022-convertible-note-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestPayableCurrentAndNoncurrent", "terseLabel": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r64", "r619" ] }, "arch_SeriesKWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesKWarrantMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-9-2021-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "Series K Warrant [Member]", "documentation": "Related to Series K Warrant." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Weighted common shares - basic and diluted (in shares)", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r34", "r35" ] }, "arch_SeriesKAndPlacementAgent2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SeriesKAndPlacementAgent2WarrantsMember", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings", "http://www.archtherapeutics.com/20220930/role/statement-note-10-2021-registered-direct-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Series K and Placement Agent 2 Warrants [Member]", "documentation": "Related to Series K and placement agent 2 warrants." } } }, "auth_ref": [] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": [ "r31", "r33" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-8-october-2019-registered-direct-offering-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionNameDomain", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited3038549B-0871-42EA-B62B-4F52BADBED91", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering", "http://www.archtherapeutics.com/20220930/role/statement-note-11-2022-convertible-note-offering-second-notes-offering-and-third-notes-offering-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-11-series-1-and-series-2-convertible-notes-details-textual", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes", "http://www.archtherapeutics.com/20220930/role/statement-note-12-series-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r31", "r33" ] }, "arch_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested, weighted average exercise price (in dollars per share)", "documentation": "Share based compensation arrangement by share based payment award options vested weighted average exercise price." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-12-income-taxes-computation-of-provision-benefits-income-taxes-from-statutory-federal-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Total Income Tax Provision / (Benefit)", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r327" ] }, "arch_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested, aggregate intrinsic value", "documentation": "Share based compensation arrangement by share based payment award options vested in period aggregate intrinsic value." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "terseLabel": "Accrued expenses and other liabilities", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "arch_ShareholderAdvancesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ShareholderAdvancesTextBlock", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-shareholder-advances-and-prefundings-related-to-the-anticipated-bridge-financing" ], "lang": { "en-us": { "role": { "label": "Shareholder Advances [Text Block]", "documentation": "The entire disclosure for share holder advances." } } }, "auth_ref": [] }, "arch_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-14-stockbased-compensation-stock-compensation-activity-details", "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-stock-compensation-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested, weighted average remaining contractual term (Year)", "documentation": "Share based compensation arrangement by share based payment award options vested weighted average remaining contractual term." } } }, "auth_ref": [] }, "arch_SharebasedPaymentArrangementAnnualIncreaseInAuthorizedSharesMaximumPercentageOfCommonStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "SharebasedPaymentArrangementAnnualIncreaseInAuthorizedSharesMaximumPercentageOfCommonStockOutstanding", "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-note-6-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "arch_SharebasedPaymentArrangementAnnualIncreaseInAuthorizedSharesMaximumPercentageOfCommonStockOutstanding", "terseLabel": "Share-based Payment Arrangement, Annual Increase in Authorized Shares, Maximum Percentage of Common Stock Outstanding", "documentation": "Maximum percentage of common stock outstanding for annual increase in authorized shares under share based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets", "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r132", "r142", "r158", "r203", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r341", "r343", "r361", "r531", "r569", "r570", "r610" ] }, "arch_ShareholderAdvancesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.archtherapeutics.com/20220930", "localname": "ShareholderAdvancesCurrent", "crdr": "credit", "calculation": { "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.archtherapeutics.com/20220930/role/statement-consolidated-balance-sheets9373A129-6377-4E68-A493-6FAF1A881564" ], "lang": { "en-us": { "role": { "label": "Shareholder advances", "documentation": "Amount as of the balance sheet date of shareholder advances, classified as current." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//820/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.13(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r547": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r549": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } }